Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A historic first for a rare disease: the FDA has approved venglustat (Infilbray; Sanofi), an oral pill that crosses the blood-brain barrier, to treat the neurological symptoms of type 3 Gaucher disease. The approval was backed by the phase 3 LEAP2MONO trial, where venglustat outperformed standard enzyme replacement therapy on measures of balance and cognition. No therapy had previously been approved for the neurological side of this condition.
A historic first for a rare disease
The FDA has approved venglustat (Infilbray; Sanofi) — the first-ever therapy targeting the neurological manifestations of type 3 Gaucher disease (GD3), a rare inherited disorder that causes harmful substances to build up in the brain, liver, spleen, and bones. Unlike existing enzyme replacement therapies (ERT) that only address systemic symptoms, venglustat is an oral, brain-penetrant pill that works by blocking a key enzyme to reduce the buildup of toxic glycosphingolipids in the central nervous system.
The approval was based on the phase 3 LEAP2MONO trial, which enrolled 43 patients (aged 12+) who had been stabilized on ERT for at least 3 years. Participants were randomized to either once-daily venglustat or continued imiglucerase infusions for 52 weeks. Venglustat significantly outperformed imiglucerase on a combined measure of ataxia (balance/coordination) and neuropsychological function.
By the Numbers
Why it matters: For patients with GD3, neurological decline — affecting balance, memory, speech, and cognition — has long been an unmet need. This approval offers the first targeted option to slow that progression, marking a significant milestone for patients, families, and clinicians managing this rare condition.